Valera Pharmaceuticals, which markets an implant for advanced prostate cancer and is developing other implants, priced its offering of 3.75 million shares at $9 on Wednesday night. The pricing came below the company's originally proposed range of $10 to $12. UBS Investment Bank and Banc of America were the lead underwriters on the deal. The stock is set to begin trading on the NASDAQ under the ticker VLRX on Thursday.
